Cite

HARVARD Citation

    Can, M. et al. (n.d.). AB0558 Accelerated infusion rates of RITUXIMAB is well-tolerated and safe in rheumatology practice: A single center experience. Annals of the rheumatic diseases. p. 670. [Online]. 
  
Back to record